SOURCE: Spotlight Innovation Inc.

Spotlight Innovation Inc.

March 16, 2016 08:30 ET

Spotlight Innovation Enters Into Research Agreement With the University of Alabama at Birmingham to Study Efficacy of Immunoplex Immunotherapy Technology for Metastatic Breast Cancer

WEST DES MOINES, IA--(Marketwired - Mar 16, 2016) - Spotlight Innovation Inc. (OTCQB: STLT) has entered into a Research Agreement with the University of Alabama at Birmingham (UAB) to conduct studies to validate the efficacy of Spotlight Innovation's Immunoplex™ immunotherapy platform technology for metastatic breast cancer in mouse models. These pre-clinical studies are anticipated to take approximately six months and are intended to validate significant and highly favorable prior test data. The data will be submitted as part of an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration. Lyse A. Norian, PhD, is the Principal Investigator. Dr. Norian conducted the original studies during her tenure at the University of Iowa.

The study protocol includes the examination of primary tumor growth in mice, the examination of metastatic tumor growth in mice with resected primary tumors, and analyses of tumor-infiltrating and systemic leukocytes in tumor-bearing mice.

Tony Vanden Bush, PhD, co-inventor of the Immunoplex™ immunotherapy platform and Spotlight Innovation's Manager of Product Development, said, "We are looking forward to validating our previous results. This is a key step in the submittal of our IND and the commencement of human clinical trials."

Cris Grunewald, President and Chief Executive Officer of Spotlight Innovation, said, "We are pleased to be cooperating, once again, with Dr. Norian in her new role at UAB, and look forward to advancing our personalized cancer tumor therapy technology to the human testing phase."

About Immunoplex™

Immunoplex™ is a vaccine platform technology that utilizes a "universal" antibody, in conjunction with a proprietary epitope "adapter," that binds to targeted antigens to treat or prevent specific diseases. Applications for the technology are solid cancerous tumors (a broad range of cancer indications) and a virtually unlimited number of viral and bacterial infections. This technology has the potential to create numerous "immune complex vaccines" for a wide range of indications. Because the Immunoplex™ therapy utilizes cancer cells from a patient's own tumor, it is a truly personalized cancer treatment.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative and proprietary platform technology candidates with a focus on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Access to platform technology candidates is accomplished via our extensive relationships with many leading academic institutions and other sources. We provide value-added development capability and funding in order to accelerate development progress. When commercially significant benchmarks have been achieved, we will partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.

Forward Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding the results of the pre-clinical studies, the ability of UAB to validate these results, and Spotlight Innovation's efforts to develop and commercialize its various technologies. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to replicate conditions under which the original results were obtained, the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information